The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Iadademstat and gilteritinib in FLT3-mutated R/R AML: dose expansion portion of the FRIDA trial
In this video, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses the dose-expansion findings from the Phase I FRIDA trial (NCT05546580), which is evaluating iadademstat plus gilteritinib in patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Fathi notes that gilteritinib is currently approved for use in this patient population and that the addition of iadademstat, an LSD1 inhibitor, may potentially enhance its activity. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
